Using the Collaborative Cross for Model Studies of Intestinal Cancer

使用协作交叉进行肠癌模型研究

基本信息

  • 批准号:
    9179477
  • 负责人:
  • 金额:
    $ 20.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-01 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

Using the Collaborative Cross for Model Studies of Intestinal Cancer Gastrointestinal (GI) cancers are worldwide health issues that are both highly prevalent and deadly. The ability to understand the genetic factors influencing the change of normal stomach, small intestine, and colorectal tissues towards the initiation, growth and progression to cancer is essential to the goals of precision medicine. As with every cancer, being able to identify people at risk before the cancer appears provides the greatest opportunity to intervene and prevent the development of life-threatening disease. To better model human disease, the Collaborative Cross (CC) was generated and has captured the tremendous genomic variation present within one mammalian species, the mouse. The CC are recombinant inbred (RI) lines created from the genomic contributions of 8 inbred founder strains, chosen because of their evolutionary diversity with each other. The unique combination of alleles within the different CC lines facilitates: 1) the identification of disease phenotypes more extreme than have been observed in common inbred laboratory strains, and 2) the opportunity for high resolution mapping of loci influencing complex traits. Our studies represent an avenue to investigate, characterize, and quantitate GI tumor phenotypes within individual CC lines. We propose to use a sensitized background, namely a mutation in the adenomatous polyposis coli (Apc) gene coupled with a resistant Mom2R allele, and mate these mice with the CC lines in a one-step cross to screen for dominant modifiers that lead to increased tumorigenesis or altered tumor profiles. We have incorporated a mutant Apc allele because the APC gene is one of the top 5 genes mutated in stomach, small intestine, and colorectal cancers in humans. The use of the CC lines coupled with the use of our unique, long-lived, but sensitized congenic strain brings an innovative approach to the in vivo study of GI cancers.
利用协作交叉进行肠癌模型研究 胃肠道(GI)癌症是世界范围内的健康问题,既高度流行又致命。的能力 了解影响正常胃、小肠、结直肠改变的遗传因素 组织对癌症的发生、生长和发展的影响对于精准医学的目标至关重要。 与每一种癌症一样,能够在癌症出现之前识别出有风险的人, 有机会干预和预防危及生命的疾病的发展。为了更好地模拟人类 疾病,协作交叉(CC)的产生,并已捕获了巨大的基因组变异 存在于一种哺乳动物物种--小鼠中。CC是由以下产生的重组近交(RI)系: 8个近交创始菌株的基因组贡献,选择这些菌株是因为它们之间的进化多样性 其他.不同CC系内等位基因的独特组合促进:1)疾病的鉴定 表型比在普通近交实验室品系中观察到的更极端,和2) 为影响复杂性状的基因座的高分辨率定位提供了机会。我们的研究代表了一种途径, 研究、表征和定量个体CC系中的GI肿瘤表型。我们建议使用 致敏背景,即腺瘤性结肠息肉病(Apc)基因突变, 抗性Mom 2 R等位基因,并将这些小鼠与CC系在一步杂交中交配以筛选显性Mom 2 R等位基因。 导致肿瘤发生增加或肿瘤特征改变的修饰剂。我们已经整合了一种变异的APC 因为APC基因是胃、小肠和结肠直肠中突变最多的5个基因之一, 人类的癌症使用的CC线加上使用我们独特的,寿命长,但敏感 同类菌株为胃肠道癌的体内研究带来了一种创新方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Linda D Siracusa其他文献

Linda D Siracusa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Linda D Siracusa', 18)}}的其他基金

Using the Collaborative Cross for Model Studies of Intestinal Cancer
使用协作交叉进行肠癌模型研究
  • 批准号:
    9308925
  • 财政年份:
    2016
  • 资助金额:
    $ 20.36万
  • 项目类别:
Use of Closely Related Inbred Strains to Identify Modifier Loci of Tumorigenesis
使用密切相关的近交株来鉴定肿瘤发生的修饰位点
  • 批准号:
    8507660
  • 财政年份:
    2012
  • 资助金额:
    $ 20.36万
  • 项目类别:
Use of Closely Related Inbred Strains to Identify Modifier Loci of Tumorigenesis
使用密切相关的近交株来鉴定肿瘤发生的修饰位点
  • 批准号:
    8356584
  • 财政年份:
    2012
  • 资助金额:
    $ 20.36万
  • 项目类别:
Modifiers of Intestinal Tumor Progression
肠肿瘤进展的调节因素
  • 批准号:
    8131384
  • 财政年份:
    2011
  • 资助金额:
    $ 20.36万
  • 项目类别:
Modifiers of Intestinal Tumor Progression
肠肿瘤进展的调节因素
  • 批准号:
    8230472
  • 财政年份:
    2011
  • 资助金额:
    $ 20.36万
  • 项目类别:
Susceptibility Genes and Colorectal Cancer
易感基因与结直肠癌
  • 批准号:
    7322476
  • 财政年份:
    2007
  • 资助金额:
    $ 20.36万
  • 项目类别:
Susceptibility Genes and Colorectal Cancer
易感基因与结直肠癌
  • 批准号:
    7848844
  • 财政年份:
    2007
  • 资助金额:
    $ 20.36万
  • 项目类别:
Susceptibility Genes and Colorectal Cancer
易感基因与结直肠癌
  • 批准号:
    7454340
  • 财政年份:
    2007
  • 资助金额:
    $ 20.36万
  • 项目类别:
Susceptibility Genes and Colorectal Cancer
易感基因与结直肠癌
  • 批准号:
    8072017
  • 财政年份:
    2007
  • 资助金额:
    $ 20.36万
  • 项目类别:
Susceptibility Genes and Colorectal Cancer
易感基因与结直肠癌
  • 批准号:
    7627303
  • 财政年份:
    2007
  • 资助金额:
    $ 20.36万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 20.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了